BioVie Inc. Increase (Decrease) in Prepaid Expense and Other Assets
BioVie Inc. (BIVI) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.46 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- BioVie Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $906.32K, a 88.67% increase year-over-year.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $551.66K, a 87.84% increase year-over-year.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $181.48K, a 22.50% increase year-over-year.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$176.01K.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for fiscal 2026 was $1.46M, a 73.09% increase from fiscal 2025.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $845.50K.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$39.91K, a 181.54% decline from fiscal 2022.
- BioVie Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $48.95K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $906.32K derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | $1.46M derived: sum of 2 quarters · filed 2026-08-13 | $1.64M derived: sum of 3 quarters · filed 2026-08-13 | $1.46M 10-K · filed 2026-08-13 |
| 2026-03-31 | $551.66K derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06 | $733.15K derived: sum of 2 quarters · filed 2026-08-06 | $557.13K S-1/A · filed 2026-08-06 | $1.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $181.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06 | $5.47K 10-Q · filed 2026-02-06 | $485.84K derived: sum of 3 quarters · filed 2026-08-13 | $779.53K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | -$176.01K 10-Q · filed 2025-11-10 | $304.36K derived: sum of 2 quarters · filed 2026-08-13 | $598.05K derived: sum of 3 quarters · filed 2026-08-13 | $746.20K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $480.37K derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | $774.06K derived: sum of 2 quarters · filed 2026-08-13 | $922.22K derived: sum of 3 quarters · filed 2026-08-13 | $845.50K 10-K · filed 2026-08-13 |
| 2025-03-31 | $293.69K derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06 | $441.85K derived: sum of 2 quarters · filed 2026-08-06 | $365.13K S-1/A · filed 2026-08-06 | $379.94K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $148.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06 | $71.44K 10-Q · filed 2026-02-06 | $86.25K derived: sum of 3 quarters · filed 2026-08-06 | -$59.13K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-09-30 | -$76.71K 10-Q · filed 2025-11-10 | -$61.90K derived: sum of 2 quarters · filed 2026-08-06 | -$207.28K derived: sum of 3 quarters · filed 2026-08-06 | -$1.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-06-30 | $14.81K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | -$130.57K derived: sum of 2 quarters · filed 2026-08-06 | -$1.34M derived: sum of 3 quarters · filed 2026-08-06 | $101.87K S-1/A · filed 2026-08-06 |
| 2024-03-31 | -$145.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | -$1.36M derived: sum of 2 quarters · filed 2025-05-12 | $87.06K 10-Q · filed 2025-05-12 | -$64.77K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11 | $232.44K 10-Q · filed 2025-02-11 | $80.61K derived: sum of 3 quarters · filed 2025-02-11 | $89.12K derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-09-30 | $1.45M 10-Q · filed 2024-11-13 | $1.29M derived: sum of 2 quarters · filed 2024-11-13 | $1.30M derived: sum of 3 quarters · filed 2024-11-13 | $1.19M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$151.83K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$143.32K derived: sum of 2 quarters · filed 2024-09-30 | -$261.16K derived: sum of 3 quarters · filed 2024-09-30 | -$39.91K 10-K · filed 2024-09-30 |
| 2023-03-31 | $8.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-14 | -$109.33K derived: sum of 2 quarters · filed 2024-05-14 | $111.91K 10-Q · filed 2024-05-14 | -$30.61K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$117.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $103.40K 10-Q · filed 2024-02-13 | -$39.12K derived: sum of 3 quarters · filed 2024-02-13 | |
| 2022-09-30 | $221.24K 10-Q · filed 2023-11-08 | $78.72K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-06-30 | -$142.53K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16 | $48.95K 10-K · filed 2023-08-16 | ||
| 2022-03-31 | $191.48K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |